could not be evaluated because it was administered only in the most severe cases. The natural history of GuillainBarr6 syndrome in children is extremely variable and more benign than in adults. Treatment with immunoglobulins should be considered in patients unable to walk. Corticosteroids are not as effective and should be withheld except when, in protracted courses, suspicion of chronic inflammatory demyelinating polyneuropathy arises. The Guillain-Barre syndrome is an immune mediated acute polyradiculoneuritis most frequently preceded by an unspecific infection.
With regard to clinical course and prognosis classical Guillain-Barre syndrome has to be differentiated from variants with accompanying central nervous system inflammation and from chronic inflammatory demyelinating polyneuropathy.I More frequently than adults, children recover after a variable span of time. However, during the acute phase of the disease disability can be severe leading to ventilatory insufficiency and even death.
Immunomodulating treatment is performed in a great number of patients, but in children, well controlled studies are lacking. The At the height of the disease, there was a significant correlation of bladder dysfunction (p<O001), cranial nerve palsies (p<000l), and a sensory deficit (p<001) with the degree of disability and the necessity of artificial ventilation. 'Axonal' NCV changes, compared with signs of diffuse demyelination or normal values, were found in older patients (median 13 v 6 years, p<002). They were indicative of a longer duration until freedom from symptoms (median 106 v 62 days, p=0 06).
There was a correlation of the maximum disability and a smaller one of the disability at admission with the outcome measures, with the exception of the time of the first signs of recovery (table 7, fig 1) . A higher rate of progression (maximum disability divided by the duration of progression) was correlated to a shorter time to the first sign of recovery (Spearman's correlation -0 35, p<0 001), but to a longer time to discharge (Spearman's correlation 0-46, p<OOOl) and to be free of symptoms (Spearman's correlation 0-31, p<O-Ol).
Comparing the parameters of disease severity between the treatment groups (table 8) , an apparent influence of the age of the children and disease severity on the decision to treat was seen. Plasmapheresis was performed in older individuals with a very high disability (75% on ventilator). Progression rate correlated with the decision to perform plasmapheresis (p<O0OOl). The group without any treatment consisted of young children with low severity (only 2-5% on ventilator). Thus, comparing treatment effects, controlling disease severity is absolutely necessary.
Regarding As treatment specific outcome measures, we additionally evaluated the time from the initiation of treatment to the first signs of recovery and to regaining independent walking. Between the groups treated with intravenous immunoglobulins or corticosteroids only, duration and rate of progression, maximum disability, the time of the initiation of treatment, and the time of first recovery were not different. However, walking ability returned significantly earlier after immunoglobulins than after corticosteroids (n=33/13, median 14 v 38 days, p<O003). The effect of Korinthenberg effect of the maximum disability was confirmed. Controlling the maximum disability, a high rate of progression was indicative of a shorter time to first recovery, to leave the hospital, and to be free of symptoms. A cerebrospinal fluid protein concentration greater than 1000 mg/l and signs of axonal damage or distal demyelination in NCV testing had a negative influence on some of the outcome measures. Treatment with intravenous immunoglobulins and corticosteroids was shown to accelerate recovery in the early phase, but not later in enabling patients to leave hospital and to become free of the last symptoms.
Discussion
Performing this retrospective multicentre study we had to choose definitions of disability and outcome variables that could be expected to be deducible from the hospital charts with a reasonable degree of reliability. However, we had to accept that not all variables would have the same high reliability. Despite this, our epidemiological and natural history data are nearly identical with previously published findings of epidemiological studies and single centre studies on childhood GuillainBarre syndrome. Children are different from adults in that the incidence seems to be higher with a younger age.9-11 In even more children than adults an acute infection preceded the neurological symptoms. In adults a high frequency of C jejuni and cytomegalovirus infections has been found,'2 13 Data on the course ofrecovery in our patients are better than in the literature. Briscoe et al reported a mean time of recovery after reaching the maximum disability of the disease of 19-3 days (5-46 days).'6 In our study the first sign of recovery was seen after a median of 17 days Natural history and treatment effects in Guillain-Barri syndrome from onset of the disease. The mean tin free of symptoms reported in the liter 120 to 180 days. 1 16 18 19 Our patientsof symptoms at a median of 64 days. experience, there is a large number of with a favourable prognosis and a sma with a more protracted course. Thus, rn the outcome in Guillain-Barre syndr mean and standard deviation is ina4 because of the non-normal distributior data. The mean values could overestin more appropriate median by nearl5
Furthermnore, in most published stuc experiences of referral centres and t hospitals are reported. Thus, a selection severe cases has to be considered whei study includes a large number of patient less severe course treated in local hospit After a variable time of follow children with acute Guillain-Barre syi reported in the literature were able l unaided. Altogether 20% to 25% still e) some degree of weakness and loss of not interfering with daily life and parti( 27 In our unidequate variate analysis, the effect of corticosteroids was a of the inferior to immunoglobulins. We found no indinate the cation that the combination with intravenous y 50%/O. immunoglobulins increased the effectiveness. lies the As a result of two large randomised studies, :eaching plasmapheresis is the treatment of choice in ofmore adults with severe Guillain-Barre syndrome. reas our The chance to improve at least one disability ts with a grade after four weeks, the duration of artificial als.
ventilation, the time to regain the ability to up, all walk independently, and the chance to regain ndrome full strength after one year are influenced to walk significantly. In 1992 a randomised study comparing plasmapheresis and intravenous immunoglobulins in adults unable to walk unaided for 10 metres was published. The results indicated a slight benefit of immunoglobulins over plasmapheresis.5 It is important to note that in both treatment groups 10% of patients experienced fluctuation of symptoms some 14 days after treatment that frequently responded to a second treatment course. Twenty five per cent of the immunoglobulin group and 34% of the plasmapheresis group were non-responders.37 38 This study has been criticised for methodological reasons and because the results of the plasmapheresis group were significantly worse than in the French and American trials.39 40 Further studies in adults are underway.41
In children, single cases with rapid improvement during administration of intravenous immunoglobulins or within four days have been observed.4 6 42-45 In reports including a larger number of children, the mean time to independent walking was two to 42 Giurses et al reported the interval from onset of the disease to maximum symptoms and from maximum symptoms to improvement to be significantly shorter in children treated with 2 g of immunoglobulin than in untreated ones. 49 The patients had been included in the groups according to the sequence of admission. However, the time differences were rather short (three and four days as a mean) and no clear description of the degree of disability at the start of treatment was given.
Our study has confirmed the treatment effect of intravenous immunoglobulin. However, given the retrospective study design, it is not possible to delineate a clear indication when and which patient to treat. We have the impression that the benefit of intravenous immunoglobulins is greatest in children who are unable to walk independently but not yet tetraplegic and ventilated. No answer to the question as to whether treatment starting earlier is of value is yet possible.
In young children with severe Guillain-Barre syndrome, due to easier performance and fewer side effects,5 paediatricians probably will prefer treatment with intravenous immunoglobulins to plasmapheresis. However, the possible consequences of high dose immunoglobulins have to be kept in mind. These have been reported as severe immunological reaction in IgA deficiency, increased intracranial pressure and aseptic meningitis, thromboembolic stroke, and renal failure.50-53 Although in our study corticosteroids were also shown to be of value, their effectiveness seems to be inferior to immunoglobulins. This and the consequences of immunosuppression in severely disabled children should preclude their use as a drug of first choice.
